

An agency of the Provincial Health Services Authority

Assessment of Injection Drug Use through Administrative Data: Implications for community level programming

Naveed Zafar Janjua MBBS, MSc, DrPH

Senior Scientist, British Columbia Centre for Disease Control Clinical Associate Professor, School of Population & Public Health, University of British Columbia, Vancouver, Canada





Web: http://bchtc.med.ubc.ca

Background

- People who inject drugs (PWID) are at high risk of hepatitis C virus (HCV), hepatitis B virus (HBV), HIV and other bloodborne infections (BBI)
- Substance use, co-occurring infections and social conditions are associated with high morbidity and mortality among PWID
- Requires the identification and enumeration of the PWID population
 - Monitoring syndemics of substance use, infections, and social conditions
 - Planning and provision of services for management






Background & Objectives

- Opioid overdose crisis in Canada and in the United States has highlighted the need for accurate estimates of the population size of PWID.
- Linked surveillance and healthcare utilization datasets, could provide a cost-effective and efficient mechanism to characterize syndemics, and better inform intervention programs and monitoring of disease outcomes among PWID
- Large administrative datasets based on the coverage of entire population of a geographic area could provide an efficient mechanism for estimating PWID population size in that geographic area.
- We identified and validated algorithms based on diagnostics codes and prescription records representing IDU in linked administrative datasets against interview-based IDU data.



BC Hepatitis Testers Cohort 1992 to 2016 Health Information on ~1.7 million British Columbians





Methods

Study Population:

 Individuals ages 11-65 years who were interviewed by public health nurses for risk factors assessment using standard case report forms at the time of their HIV, HBV or HCV diagnosis as part of provincial surveillance of blood borne infections according to provincial guidelines.

IDU algorithms in administrative datasets

- IDU was identified through:
 - diagnostic codes for drug use and injecting-related infections such as skin and soft tissue infections from medical visit and hospitalization datasets and
 - dispensation records of prescription drug used for the management of opioid addiction including methadone and buprenorphine/naloxone

Added data from emergency department visits recently



ICD codes for defining IDU

Diagnoses ICD-9 and ICD-10 codes in medical visit and hospitalization data			
Drug use diagnoses			
Opiates	E8500*, 3040*, 3047*, 3055*, 9650*, F11*, T400, T401, T402, T403, T404, T406, R781		
Cocaine	3042*, 3056*, 970*, F14*, T405, R782,		
Amphetamines	3044*, 3057*, 9697*, F15*, T436		
Sedatives	3041*, 9694*, 3054*, F13*, T423-T428,		
Other	292*, 3045*, 3046*, 3048*, 3049*, 3053*, 3059*, 6483*, 7960*, 9621*, 9658*, 9663*, 9664*, 9670*, 9684*, 9685*, 9696*, 9698*, 9699*, 970*, V6542, , F19*, Z715*, Z503*, T42*, T387,T408, T409, T412,T436-T439, T439, T507		
Fee item (OST)	39		
DIN/PINs for OST	2242963, 2242964, 999792-3, 66999990-3, 66999997-9, 67000000-4, 2295695, 2295709, 2408104, 2424851, 2424878, 999776, 22123346-9, 655619, 655627, 781460, 781479, 2408090		
Infections			
Endocarditis	1128, 11281, 421*, 424*, B376, I33*-I37*, I38, I39*		
Bacteremia or Sepsis	038*, 4151, 41512, 4229, 42292, 449*, 7855*, 7907*, 9959, 99590-2, A40*, A41*, I269, I400, R572, R651, R659		
Osteomyelitis	7300*-7302*, 7309*, M86*, M899*		
Skin or soft tissue infections	0400*, 324*, 326*, 451*, 5672, 56722, 56731, 56738, 5695*, 5720*, 5901*, 681*, 682*, 7071*, 7078*, 7079*, 7098*, 7236*, 72886, 7293, 72930, 72939, 7854*, I80*, L97*, L988, M793*, A480, G06*, G09, K630, K650, K750, L02*, L03*, M5402, M726*, N10, R02		
BC Centre for Disease Control	oid substitution therapy; DIN: Drug identification number; uct identification numbers; * starts with		

Performance characteristics of various IDU algorithms

Code	Description	Sensitivity	Specificity	PPV	NPV	
Algorithms for Drug Misuse (DM)						
DM-1M	1 medical visit or 1 hospitalization for illicit drug use or drug misuse	90	73	65	93	
DM-2M	2 medical visit or 1 hospitalization for illicit drug use or drug misuse	87	77	69	91	
Algorithms for Injection Drug Use (IDU)						
IDU-1M	1 medical visit or 1 hospitalization for injectables	80	81	71	88	
IDU-2M	2 medical visits or 1 hospitalization for injectables	78	83	73	87	
IDU-1M OST	1 medical visit, 1 hospitalization for injectables or record for OST	85	80	70	90	
IDU-2M OST	2 medical visit, 1 hospitalization for injectables or record for OST	83	82	72	90	
Algorithms for Injection Drug Use (IDU) and/or injecting-related infection (IRI)						
IDU- 2M + IRI 2yr	(2 medical visits or 1 hospitalization for injectables) AND injecting-related infection					
	code within 2 years of a qualifying code	60	90	78	80	
IDU-2M OST+ IRI 2yr	(2 medical visit or 1 hospitalization for injectables or record for OST) AND injecting-					
	related infection code within 2 years of a qualifying code	65	90	78	82	
IDU- 2M + IRI 1yr	(2 medical visits or 1 hospitalization for injectables) AND injecting-related infection					
	code within 1 year of a qualifying code	57	92	79	79	
IDU- 2M OST + IRI 1yr	(2 medical visit or 1 hospitalization for injectables or record for OST) AND injecting-					
	related infection code within 1 year of a qualifying code	62	91	79	81	
IDU-2M IRI	2 medical visits or 1 hospitalization for injectables or injecting-related infection code	91	43	48	90	
IDU-2M OST IRI	2 medical visits or 1 hospitalization or record for OST or injecting-related infection	94	42	48	92	
IRI	Injection-related infection	82	46	47	82	

Performance characteristics of various IDU algorithms from hospitalization data

Code/Abbreviation	Description	Sensitivity	Specificity	PPV	NPV
IDU-H	1 hospitalization for injectables	73	85	74	85
IDU-H OST	1 hospitalization for injectables OR record for OST	82	84	74	89
IDU-H IRI	1 hospitalization for injectables OR Injecting-related				
	infections	77	77	66	86
IDU-H OST IRI	1 hospitalization for injectables OR record for OST OR				
	injecting-related infections	85	76	66	90
IDU-H + IRI 1yr	1 hospitalization for injectables AND Injecting-related				
	infections within 1 year of a qualifying code	38	96	83	73
IDU-H OST + IRI 1yr	(1 hospitalization for injectables OR record for OST) AND				
	injecting-related infections within 1 year of a qualifying code	40	96	83	74
IDU-H + IRI 2yr	1 hospitalization for injectables AND Injecting-related				
	infections within 2 year of a qualifying code	40	95	83	74
IDU-H + IRI 2yr	(1 hospitalization for injectables OR record for OST) AND				
	injecting-related infections within 2 year of a qualifying code	41	95	83	74





Performance of various IDU algorithms including ER data

	Description	Sensitivity	Specificity	PPV	NPV
2m_0n_1d_0p_er	IDU based on 2 MSP/ 0 NACRS/ 1 DAD/ No OST	77.6	83.3	72.5	86.8
2m_1n_1d_0p_er	IDU based on 2 MSP/ 1 NACRS/ 1 DAD/ No OST	78.9	81.6	70.8	87.2
2m_2n_1d_0p_er	IDU based on 2 MSP/ 2 NACRS/ 1 DAD/ No OST	78.2	82.8	72.1	87.0
2m_3n_1d_0p_er	IDU based on 2 MSP/ 3 NACRS/ 1 DAD/ No OST	77.8	83.0	72.2	86.8

EVER - IDU based on 2 MSP/ 1 NACRS/ 1 DAD/ OST: N=105,951 unique individuals

2013 to 2015 - IDU based on 2 MSP/ 1 NACRS/ 1 DAD/ OST/: N=45,610 unique individuals








BC Centre for Disease Control An agency of the Provincial Health Services Authority

Use and Application


PWID population size estimates by local health areas in British Columbia, Canada (2013-2015)



British Columbia




Distribution of IDU in British Columbia 2009–2013








Distribution of HCV in British Columbia Kernel density Estimation maps 2009-2013








HCV cascade among past PWID in British Columbia, December 31, 2016



HCV cascade among recent PWID in British Columbia, December 31, 2016




BC Centre for Disease Control


14,000

British Columbia Hepatitis Testers Cohort

Comparison of HCV Cascade by Injection Drug Use



Cumulative incidence curves for reinfection following SVR by injection drug use history



Rossi C et al. J Hepatol. 2018 https://doi.org/10.1016/j.jhep.2018.07.025

British Columbia Hepatitis Testers Cohort

Interpretation and Caveats

- Algorithms based on administrative datasets

 Misclassification
 - Under ascertainment due to coding practices
- Health care utilization dependent

Access and frequency of use affect assessment

- No method for estimation of PWID population size perfect
- Overall PWID population size estimates a guide







- Diagnostic codes based algorithms could be used to identify injection drug use in administrative datasets.
- Enables an assessment of the distribution of PWID at population level which can help in planning harm reduction services and overdose response at the local community level.
 - Estimates being used for harm reduction supplies planning in BC
- Could be used for providing testing, care and treatment, and to examine the linkage to care for HCV, HIV, mental illness and other conditions among PWID in small geographic areas.
- Cascade of prevention services for HCV at local level
 - NSP, OST, mental health services
- Local cascade of care for substance use services





Acknowledgements

- BCCDC
 - The BC-HTC Team
 - Public Health Analytics
 - PMR, PHSA
- BCCA
- Ministry of Health
- All data stewards
- Canadian HCV Network

- Funding:
 - BCCDC
 - Canadian Institute of Health Research





Thank you!

Email: naveed.janjua@bccdc.ca Web: http://bchtc.med.ubc.ca



BC Centre for Disease Control

An agency of the Provincial Health Services Authority